The rearrangements cause altered dosage of PMP22 that subsequently results in neuropathy; overexpression causes CMT1A whereas underexpression (i.e., haploinsufficiency) leads to HNPP. Here, PMP22 is linked to hereditary neuropathy with liability to pressure palsies.